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illusTraTive case 
a 45-year-old man presents to your out-
patient clinic within 24 hours after onset 
of left-sided facial nerve weakness and 
inability to smile on one side of his face. 
He asks for a therapy to help improve his 
symptoms quickly, as his daughter is  
getting married in a few months, and he 
will be in the wedding pictures.
   Is there a treatment that will hasten his 
complete recovery?
background
z		Insufficient	statistical		
power	until	now
Many of us treat patients with Bell’s palsy 
with both corticosteroids and antiviral 
medications, such as acyclovir or vala-
cyclovir, largely on the basis of patho-
physiologic reasoning, because we’ve 
had no clear guidance from outcome 
studies. Until now, outcome studies 
have had mixed findings, and have been 
inconclusive.2 Most outcome studies 
have lacked the statistical power to ei-
ther detect or to rule out potential ben-
efits convincingly. The study by Sullivan 
and colleagues is the first to have a suf-
ficiently large study sample from which 
to draw more definitive conclusions 
based on patient-oriented outcomes.
Steroid	plus	antiviral	makes	
sense,	pathophysiologically
Corticosteroids are thought to decrease 
inflammation of the facial nerve dur-
ing an episode of facial paralysis. Some 
have postulated that herpes simplex virus 
type I may be a cause of facial nerve paral-
ysis, hence the treatment with antivirals.3
Most of our PURL surveillance sys-
tem clinician reviewers said that they pre-
scribe both corticosteroids and antivirals.
Guidelines:	“probably,	possibly”
For example, a report of the Quality 
Standards Subcommittee of the Ameri-
can Academy of Neurology concluded 
that benefit from both steroids and 
antivirals has not been well established 
in patients with Bell’s palsy. However, 
the report states that evidence suggests 
that steroids are safe and probably 
effective, while antivirals are also safe 
and possibly effective.4 
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a 10-day course of cortico-
steroids (prednisolone 25 mg 
twice daily) started within 72 
hours significantly improves 
the chances of complete 
recovery. There is no added 
benefit from acyclovir.1
Strength of recommendation 
a: Based on a large, well-designed 
randomized controlled trial
Sullivan FM, Swan Ir, Donnan PT, et al. Early 
treatment with prednisolone or acyclovir in Bell’s 
palsy. N Engl J Med 2007; 357:1598–1607.
Practice changer 
PURLs methodology
This study was selected and 
evaluated using FPIN’s Priority 
Updates from the Research 
Literature (PURL) surveillance 
system methodology. The 
criteria and findings leading to 
the selection of this study can 
be accessed at www.jfponline.
com/purls. 
New feature
Adding acyclovir   
to prednisolone 
does not improve 
chances of full 
recovery
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In contrast, UpToDate suggests 
treating all patients seen within a week 
of symptom onset with corticosteroids 
(prednisone 60–80 mg daily) plus valacy-
clovir (1 g 3 times daily) for 1 week.5
clinical conTexT 
z		Quality	of	life,	risk		
of	permanent	harm
Bell’s palsy, defined as an acute periph-
eral facial weakness of unknown cause, 
has an annual incidence of 20 to 32 per 
100,000. Most patients recover com-
pletely, with or without treatment, but 
20% to 30% can have permanent facial 
weakness or paralysis. 
The time to resolution is a quality of 
life issue for those in whom disease does 
not resolve spontaneously.6 
We think that this study provides 
convincing evidence that acyclovir is 
not indicated for Bell’s palsy and that 
corticosteroids are.
sTudy summary 
z		10-day	treatment,	
starting	promptly
This double-blind, placebo-controlled, 
randomized, multifactorial trial com-
pared recovery of facial nerve function 
for patients randomized to receive 10 
days of treatment with prednisolone (25 
mg twice daily), acyclovir (400 mg 5 times 
daily), both agents, or placebo (lactose).
Inclusion	criteria
Patients had to be at least 16 years of age 
(average age=44), with unilateral facial 
nerve weakness of no identifiable cause 
(eg, a diagnosis of Bell’s palsy). They 
were recruited mostly through their 
family doctors (75%) but also through 
emergency rooms and dental offices, and 
were referred to otolaryngologists at 17 
Scottish hospitals within 72 hours. 
The degree of initial facial paraly-
sis was moderate to severe, based on 
the House-Brackmann scale, a widely 
used system for grading recovery from 
facial nerve paralysis. After the onset 
of symptoms, most patients (53.8%) 
initiated treatment within 24 hours, 
32.1% within 48 hours, and 14.1% 
within 72 hours. Patients were assessed 
at baseline, 3 months, and 9 months.
Exclusion	criteria
Exclusion criteria included pregnancy, 
breastfeeding, uncontrolled diabetes 
(Hb A1c >8.0%), peptic ulcer disease, 
suppurative otitis media, herpes zoster, 
multiple sclerosis, systemic infection, 
sarcoid or other rare disorder, and in-
ability to give informed consent.
Primary	outcome:	
Complete	recovery
The study was designed to test the effec-
tiveness of prednisolone and acyclovir’s 
effects on facial nerve recovery. The 
House-Brackmann scale was used to score 
recovery. The scale divides patients into 1 of 
6 categories depending on the severity 
of facial nerve dysfunction, with grade 1 
describing normal function and grade 6 
indicating total paralysis. 
Most of our  
clinician reviewers 
said they  
prescribe both 
corticosteroids 
and antivirals 
although most patients with Bell’s palsy recover  
completely, with or without treatment, 20% to 30%  
can have permanent facial weakness or paralysis.
f i g u r e
Facial	weakness	or	paralysis	
may	be	permanent
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The scale was applied to photographs 
of patients taken while smiling, raising 
eyebrows, at rest, and closing eyes. The 
photographs were assessed and graded 
independently by 3 experts: an otolar-
yngologist, a neurologist, and a plastic 
surgeon. They were unaware of the study 
group assignment or stage of assessment. 
Of 496 patients who completed the 
study, 357 recovered fully at 3 months, 
with no further treatment needed. Of the 
remaining patients, 80 had fully recov-
ered at 9 months and 59 still had some 
facial-nerve deficit. At 3 months, there 
was a significant difference in recovery 
rates in prednisolone comparison groups: 
83% with prednisolone vs 63.6% with-
out prednisolone, a difference of 19.4 
percentage points (95% confidence in-
terval [CI], 11.7 to 27.1; P<.001, num-
ber needed to treat [NNT]=5). There was 
no significant difference in recovery rates 
in acyclovir comparison groups: 71.2% 
with acyclovir vs 75% not treated with 
acyclovir, a difference of 4.5 % percentage 
points (95% CI, –12.4 to 3.3; unadjusted 
P=.30; adjusted P=.50). At 9 months, the 
rates of complete recovery were 94.4% 
in prednisolone treated groups vs 81.6% 
in no prednisolone treatment groups 
(NNT=8) (TABLE).
Adverse	events
Adverse events included an expected  range 
of minor symptoms associated with use of 
prednisolone and acyclovir, such as dizzi-
ness and vomiting. During the study, 3 pa-
tients died under circumstances unrelated 
to treatment: 2 were receiving double pla-
cebo and 1 received only acyclovir.1
whaT’s new  
z		A	treatment	based	on		
patient-oriented	evidence
Neither corticosteroids nor antivirals are 
new treatments for Bell’s palsy. What is 
new is that we know what works (corti-
costeroids) and what does not work (an-
tivirals). This randomized controlled trial 
finally gives us the evidence on patient-
oriented outcomes that we need to make 
confident recommendations, primarily 
because it enrolled twice as many patients 
as all trials compiled for the Cochrane 
systematic reviews on this topic.7,8 
As an interesting side note, this is a 
good case study of how pathophysiolog-
ic reasoning sometimes leads us to good 
medical practice (corticosteroids in this 
case) and sometimes does not (antivirals 
in this case). 
Isn’t it good to know that we can ac-
tually help patients with Bell’s palsy with 
corticosteroids and that antivirals are not 
necessary?
caveaTs  
z		Valacyclovir
Hato et al,9 in a Japanese study, showed 
that valacyclovir reaches a level of bio-
This study  
included twice as 
many patients  
as were included 
in the Cochrane 
systematic reviews
Complete	recovery	was	significantly	higher	in	the	group		
that	received	prednisolone	without	an	antiviral
 acyclovir arm Placebo arm
 acyclovir + acyclovir + Placebo + Placebo + 
 Prednisolone Placebo Prednisolone Placebo
number of patients  
who completed therapy  124  123 127 122
% complete recovery*  
at 9 months 92.7% 78.0% 96.1% 85.2%
* Grade 1 on House-Brackmann scale, indicating normal function.
Source: adapted from Sullivan et al.1
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Bell’s palsy
availability that is 3 to 5 times more than 
acyclovir and may add some benefit to 
recovery when used in conjunction with 
prednisolone, particularly in more severe 
cases of Bell’s palsy. 
The Hato study was a prospective, 
multicenter, randomized, placebo-con-
trolled study that investigated the effects 
of valacyclovir (1000 mg/d for 5 days) 
and prednisolone in comparison with the 
effects of placebo and prednisolone for 
the treatment of Bell’s palsy.
The study outcomes included com-
plete recovery from palsy; patients were 
followed until recovery occurred or more 
than 6 months in cases with severe prog-
nosis. The patients in the Hato study had 
an average Yanagihara score of 15 when 
rating their facial palsy (which falls be-
tween House–Brackmann grades 4 and 
5). 
The overall rate of recovery of those 
treated with valacyclovir and predniso-
lone (96.5%) was significantly better 
(P<.05) than the rate among those treated 
with placebo and prednisolone (89.7%). 
In cases of complete or severe palsy, the 
rates of patients treated with both agents 
vs prednisolone alone who recovered were 
95.7% (n=92) and 86.6% (n=82) (P<.05; 
NNT=11).
one big difference between the Sullivan 
and Hato studies is that the patients re-
cruited for the Hato study had much more 
severe facial palsy (rated between 4 and 5) 
than in the Sullivan study (average=3.6), 
which suggests that there may be a use for 
valacyclovir in treating patients with com-
plete facial palsy.6 Patients were all recruit-
ed from tertiary care centers as opposed to 
mainly from primary care settings as in the 
Sullivan study, consistent with the greater 
severity of cases in the Hato study. 
outcome assessors were not blinded to 
treatment assignments or stage of assess-
ment in the Hato study, raising major 
concerns about the validity of the find-
ings given the nature of facial paralysis 
as an outcome measure. We find the Sul-
livan study a more rigorous and convinc-
ing study. Nonetheless, future research 
may verify their findings and support 
the use of valacyclovir in the most severe 
cases of Bell’s palsy. For now, we are not 
convinced.
challenges To imPlemenTaTion 
z		Easy	to	put	into	practice	
Thankfully, some changes in practice are 
easy to implement. This is one of them. 
For those who prefer to prescribe predni-
sone, the dose of prednisolone used in the 
study, 25 mg bid, is equivalent to 60 mg 
of prednisone.   n
Purl surveillance system methodology 
This study was selected and evaluated using FPIN’s Pri-
ority updates from the research literature (Purl) sur-
veillance system methodology. Both the methodology 
and the criteria and findings leading to the selection of 
this study as a Purl can be accessed at www.jfponline.
com/purls.
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Prednisolone  
25 mg twice daily   
is equivalent to  
60 mg prednisone 
